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Risk Factors for Long-Term Coronary Artery Calcium Progression in
the Multi-Ethnic Study of Atherosclerosis
Amanda J. Gassett, MS; Lianne Sheppard, PhD; Robyn L. McClelland, PhD; Casey Olives, PhD; Richard Kronmal, PhD;
Michael J. Blaha, MD, MPH; Matthew Budoff, MD; Joel D. Kaufman, MD, MPH
Background-—Coronary artery calcium (CAC) detected by noncontrast cardiac computed tomography scanning is a measure of
coronary atherosclerosis burden. Increasing CAC levels have been strongly associated with increased coronary events. Prior
studies of cardiovascular disease risk factors and CAC progression have been limited by short follow-up or restricted to patients
with advanced disease.
Methods and Results-—We examined cardiovascular disease risk factors and CAC progression in a prospective multiethnic cohort
study. CAC was measured 1 to 4 times (mean 2.5 scans) over 10 years in 6810 adults without preexisting cardiovascular disease.
Mean CAC progression was 23.9 Agatston units/year. An innovative application of mixed-effects models investigated associations
between cardiovascular disease risk factors and CAC progression. This approach adjusted for time-varying factors, was flexible
with respect to follow-up time and number of observations per participant, and allowed simultaneous control of factors associated
with both baseline CAC and CAC progression. Models included age, sex, study site, scanner type, and race/ethnicity. Associations
were observed between CAC progression and age (14.2 Agatston units/year per 10 years [95% CI 13.0 to 15.5]), male sex
(17.8 Agatston units/year [95% CI 15.3 to 20.3]), hypertension (13.8 Agatston units/year [95% CI 11.2 to 16.5]), diabetes
(31.3 Agatston units/year [95% CI 27.4 to 35.3]), and other factors.
Conclusions-—CAC progression analyzed over 10 years of follow-up, with a novel analytical approach, demonstrated strong
relationships with risk factors for incident cardiovascular events. Longitudinal CAC progression analyzed in this framework can be
used to evaluate novel cardiovascular risk factors. ( J Am Heart Assoc. 2015;4:e001726 doi: 10.1161/JAHA.114.001726)
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C oronary artery calcium (CAC) has been consistentlyassociated with cardiovascular disease (CVD) in both
clinical trials and observational research.1–5 Although most
often studied as a 1-time measure of atherosclerosis extent
and a risk marker of future ischemic CVD events, it can also
be assessed over time. CAC progression, defined as the
change in quantity of CAC over time, is itself a predictor of
CVD events and has been shown to be predictive of events in
a prospective cohort.2,4 As a noninvasive surrogate for
evaluating risk factors for CVD, CAC progression has shown
promise, although prior studies had limited duration of follow-
up.
The Multi-Ethnic Study of Atherosclerosis (MESA) was
designed to investigate the progression of CVD in a well-
characterized, diverse, prospective cohort over a long period
of time to generate a body of work that would generalize to a
wider US population than has traditionally been the focus of
cardiovascular research. An initial analysis of CAC progression
was conducted in the MESA cohort after 2.4 years of follow-
up.6 The initial analysis separated participants into those with
no CAC at baseline and those with any CAC at baseline.
Incidence (development of any CAC between 2 examinations)
and progression among those with any CAC initially were
investigated independently.
Building on that prior work, we analyzed CAC progression
with 10 years of follow-up time within the MESA cohort, with
up to 4 measurements per participant. We applied innovative
statistical methods to allow an integrated assessment of all
participants and all repeated measures. We hypothesized that
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this approach would provide a sensitive method of assessing
risk factors for progression of atherosclerosis that could be
used to evaluate additional risk factors in epidemiological
research.
Methods
Study Population
MESA is a large, multicenter, prospective cohort study that
has been described previously.7 Participants in MESA com-
pleted as many as 5 clinic visits and 14 follow-up phone calls.
Timing of clinic visits was as follows: exam 1 in 2000 to 2002,
exam 2 in 2002 to 2004, exam 3 in 2004 to 2006, exam 4 in
2005 to 2007, and exam 5 in 2010 to 2012. This study was
approved by the institutional review boards at each center
and at the University of Washington, and all subjects gave
written informed consent.
Measurement of CAC
All participants were scanned by noncontrast cardiac com-
puted tomography (CT) during exam 1 using methods that
have been described previously.6,8 By design, about half of the
participants were scanned again during exam 2 (n=2914), and
the other half were scanned during exam 3 (n=2925). The
exam 4 selection strategy prioritized participants without
exam 3 scans and included CT scans for 1349 participants.
During exam 5, a total of 3304 participants received CT scans,
preferentially including participants with scans from exam 3
and/or exam 4. Scans that were obtained subsequent to
coronary revascularization procedures that were performed
after exam 1 were excluded from this analysis. Participants
were advised of their CAC scores following each examination,
and 76% of participants requested that these results be
released to their physicians, along with an interpretation of
the score as average or as below or above average for age and
sex, without recommendations for management.9
Scanner models varied across centers and time. During
exams 1 to 3, 3 centers used electron beam CT technology
and 3 used multidetector CT technology.6 The latter technol-
ogy was in use at all centers by exam 5. Consistent calibration
of scans was conducted using a “phantom” that was
described previously.8
CAC scores were calculated according to the methodology
of Agatston et al.10–16 Calcified lesions of at least 4 adjacent
voxels above a threshold of 130 Hounsfield units (HU) were
identified; below this, scans were assigned a zero value.
Volume of each calcified lesion was then multiplied by a
coefficient based on the brightest voxel it contained (coeffi-
cient of 1 for a maximum of 130 to 199 HU, 2 for 200 to
299 HU, 3 for 300 to 399 HU, 4 for a maximum >400 HU).
The Agatston score was calculated as the sum of the within-
plane scores across all calcified lesions.
Measurement of Cardiovascular Risk Factors
The risk factors of interest included age, sex, race/ethnicity,
education, household income, neighborhood socioeconomic
status index,17 systolic and diastolic blood pressure, body
mass index (BMI), low-density lipoprotein cholesterol (LDL-C),
high-density lipoprotein cholesterol (HDL-C), triglycerides,
total cholesterol, statin use, antihypertensive use, smoking
status, pack-years of smoking, exposure to second-hand
smoke (yes/no), diabetes status, family history of CVD,
fibrinogen, (high sensitivity) C-reactive protein, and creatinine.
The questionnaires and physical examinations used in MESA
were described previously.7 Family history of CVD was
ascertained by questionnaire during the second in-clinic
follow-up examination, and family history of premature CVD
was defined as myocardial infarction/heart attack, stroke/
brain attack, or cardiovascular procedure (coronary bypass or
balloon angioplasty) in a female primary relative (parent,
sibling, or child) aged <65 years or a male primary relative
aged <55 years. Neighborhood socioeconomic status index
was calculated for the census tract in which participants lived
during exam 1.17
Most health metrics and demographics were defined at
exam 1 and considered to be static. Potential risk factors that
were assessed at later exams but that were also considered
to be static included family history of premature CVD
(assessed at exam 2) and household income (defined as
average midpoint of self-reported income category across all
available examinations, with a value of $125 000 used for
participants indicating an income greater than $100 000).
As a sensitivity analysis, we examined the relationship
between CAC progression and smoking status as classified by
the MESA Lung substudy. The MESA Lung substudy confirmed
smoking status by urinary cotinine levels (Immulite 2000
Nicotine Metabolite Assay; Diagnostic Products Corp). Partic-
ipants with cotinine levels >500 ng/mL were classified as
current smokers, regardless of self-report. Never-smokers at
exam 1 that reported being former smokers at later exam-
inations were also reclassified as former smokers.18
Analysis
We analyzed the association between CVD risk factors and
CAC progression using a mixed-effects model. Risk factors for
CAC progression were analyzed in both minimally and more
fully adjusted models (described in detail in “Minimally
Adjusted Models”); in both cases, CAC was modeled contin-
uously on the natural scale. The use of statins was considered
as both static, defined as in use at exam 1, and time varying,
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defined as in use at the time of the clinical examination
concurrent with CT scan. To further investigate the associa-
tion between statin use and CAC progression, we created a
categorical variable delineating participants who were using
statins at exam 1, those who had never used statins, and
those who had started using statins during follow-up. This
variable was evaluated as a separate risk factor.
Minimally Adjusted Models
Our primary approach used minimally adjusted models. We
analyzed the association between each risk factor and CAC
progression in models that, in all cases, included age at exam
1, sex, race/ethnicity, metropolitan area or study site, and
scanner type. In addition, in evaluating the association
between CAC progression and cholesterol (total, HDL-C,
LDL-C, and triglycerides), we further adjusted for statin use at
exam 1. In evaluating the association between CAC progres-
sion and systolic or diastolic blood pressure, we adjusted for
antihypertensive medication use at exam 1. In evaluating the
association between CAC progression and antihypertensive
medication use, we adjusted for hypertensive diagnosis. The
associations between CAC progression and both pack-years
of cigarette smoking and second-hand smoke exposure were
adjusted for smoking status (never, former, current). Partic-
ipants with missing data were dropped from analyses that
included those variables.
Fully Adjusted Models
Our secondary approach considered a more fully adjusted
model, chosen using backward selection. Because backward
selection algorithms are optimized for ordinary least squares
regression, we used a simplified outcome—individually
calculated annual CAC progression—to select variables for
a fully adjusted model.
Variables considered included age at exam 1, sex, race/
ethnicity, metropolitan area or study site, BMI, smoking
status, total cholesterol, HDL-C, LDL-C, diabetes status, statin
use at exam 1, systolic and diastolic blood pressure,
hypertension, education, income, neighborhood socioeco-
nomic status index, and family history of CVD. Model fit
was assessed using the Akaike information criterion.
Additional Sensitivity Analyses
Alternative adjustment models excluded indicators for CT
scanner model or adjustment for metropolitan area. We
assessed the sensitivity of the results to the outcome
distribution by excluding the participants with the highest
CAC progression, using cutoffs of 250 and 150 Agatston
units/year, and by restricting the analysis to participants with
>0 Agatston units of CAC at exam 1. We evaluated the
sensitivity of the association between CAC progression and
statin use by comparing statin use at exam 1 with time-
varying statin use.
Mixed-effects Model
The mixed-effects model that we used in this analysis jointly
modeled the cross-sectional and longitudinal relationships
between CVD risk factors and CAC. The cross-sectional terms
modeled an estimated baseline and control for that baseline.
The cross-sectional relationships between CVD risk factors
and CAC can produce biased results in a progression analysis
that controls for measured baseline.19,20 Any measurement
error exacerbates this bias.19,20 Adjusting for an estimated
baseline allowed us to control for cross-sectional confounding
without inducing bias.
The mixed-effects model provides 2 additional benefits:
(1) Participants with a variable number of observations, or
even a single observation, can be included in the analysis;
and (2) the assumption that data are missing completely at
random is not required. Consequently, selection bias is of
less concern using this method compared with methods that
require full follow-up for all participants or the “missing
completely at random” assumption, such as generalized
estimating equations or repeated-measures analysis of
variance.
The specific form of the model is as follows, with
participants indexed by i and exams indexed by v:
Yiv ¼ ½a0 þ Xi0a1 þ ai þ ½tivb0 þWivtivb1 þ tivbi
þ ½Uivc1 þ eiv
This model uses the following definitions: Yiv indicates CAC
measurement for subject i at vth follow-up exam; Xi0, time-
invariant cross-sectional confounders and risk factors at exam
1 for participant i; Wiv, possibly time-varying longitudinal
confounders and risk factors at exam v for participant i; Uiv,
time-varying variables to adjust measurements at exam v for
participant i; tiv, time in years from exam 1 to the vth follow-up
exam for participant i; b0, CAC progression (annual rate of
change) in average participants in the reference group; b1,
coefficients for associations between confounders and risk
factors and rate of CAC progression (this is the term of
interest); a0, average CAC measurement at exam 1 for
participants in the reference group; a1, coefficients for
associations between exam 1 CAC measurements and risk
factors or confounders; c1, coefficients for cross-sectional
associations between time-varying variables and CAC mea-
surements at all exams; ai, participant-specific random
intercept; bi, participant-specific random slope; eiv, error
associated with Yiv.
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The model is composed of 3 parts, separated above by
square brackets: (1) the cross-sectional relationship between
the amount of CAC at exam 1 and values of covariates at
exam 1, (2) the longitudinal relationship to model rate of
change, and (3) time-varying “transient” terms that adjust for
variables relevant to specific measurements. The cross-
sectional terms in the model are equivalent in interpretation
to terms from a cross-sectional model of the outcome at
exam 1. These fixed effects (a1), together with the random
intercepts (ai), model participant-specific intercepts. The
longitudinal terms model an overall progression rate (b0),
interpreted as the rate of change of CAC for a participant with
no additional risk factors (ie, all terms Wi=0), and incorporate
terms that adjust that rate (b1) according to the association
between progression rate and risk factors. Values of covari-
ates included in the transient part (Uiv) are time varying, but
the transient adjustment does not modify the slope. The
transient terms serve to adjust follow-up measurements that
were measured under different conditions from the original.
Removing systematic differences due to different conditions
allows the slope to be estimated based on the measurements
as if they had been taken under the same conditions.
This mixed-effects model leverages information from all
participants, including those without follow-up measurements,
to jointly model the amount of CAC at exam 1 and CAC
progression over time, thereby adjusting progression for
modeled baseline extent. Each CVD risk factor was included
as both a cross-sectional term and with an interaction with
time. CT scanner model was included as a transient adjust-
ment. We included subject-specific random intercepts and
random slopes. Continuous covariates other than follow-up
time were mean centered and scaled to a reasonable
increment prior to analysis.
P values were calculated using Satterthwaite’s approxima-
tion of denominator degrees of freedom for F statistics. All
analyses were conducted using R 3.0.1 (R Foundation).21
As a sensitivity analysis and for completeness, a simplified
model using annual change between exams 1 and 5 as the
outcome was fit to the subset of participants with measure-
ments available at exam 5. These results were compared with
those derived from fitting the above mixed-effects model to
the same subset of participants.
Results
Of the 6814 participants recruited to MESA, 744 had CAC
scores only at exam 1, and 6066 had a score at both exam 1
and at least 1 follow-up exam. Four participants had exam 1
scans that could not be scored. There were 166 participants
that were scanned at least once after a coronary revascular-
ization procedure and whose postprocedure measurements
were excluded. The number, timing, and exclusion of obser-
vations are described in Figure. The overall average CAC
progression was 23.9 Agatston units/year among partici-
Recruited: 6814
Score at E1: 6810 Have Follow-up Scores: 6066
2 Scores: 2451
Last Score E2 or E3: 2305
E4 Score: 125 
E5 Score: 21
No Follow-up
1 Score: 744
3 Scores: 2830
Last Score E4: 331
Last Score E5: 2499
4 Scores: 785
Last Score E5
1 Score Used for 
Cross-sectional 
Piece of Model: 817 
2 Scores Used: 2503
Last Score E2 or E3: 2364
Last Score E4: 120
Last Score E5: 19
3 Scores Used: 2726
Last Score E4: 322
Last Score E5: 2404
4 Scores Used: 
764
Last Score E5
Coronary Revascularization: 166
Before E2 or E3: 61
Before E4: 32
Before E5: 73
74
4 33
24
18
27
1811
2
21
76
4
73 85 8
Figure. Total number of participants included and excluded, distinguished by number of participant-
specific observations used in the analysis. No participants were scanned during both exam 2 (E2) and exam
3 (E3). Scores after coronary revascularization procedures were excluded.
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pants with at least 2 measurements (range 365 to 834, IQR
0.3 to 21.7, with a median progression rate of 3.0 Agatston
units/year). At baseline, 50% of the cohort had no CAC; by
exam 5, this proportion had dropped to 31%.
Characteristics of the study population are provided in
Table 1. Participants with at least some follow-up were similar
to the initial cohort in terms of race/ethnicity, sex ratio, BMI,
cholesterol, baseline statin use, and smoking behavior.
Participants whose last follow-up was at exam 5 tended to
be slightly younger and more educated and to have higher
income, less prevalence of diabetes, and lower blood pressure
compared with participants who were lost to follow-up or
died. Participants with longer follow-up also had noticeably
less CAC at exam 1.
The primary results for this analysis are based on minimally
adjusted models to show the most direct associations
between the risk factors and CAC progression. These are
presented in the first column of Table 2. Age at exam 1 and
sex were both strongly associated with increased CAC
progression. Among the racial/ethnic groups, black race
was associated with decreased CAC progression compared
with white race, whereas CAC progression among participants
with Hispanic ethnicity or Chinese ancestry were not signif-
icantly different from CAC progression among white partic-
ipants in the minimally adjusted model. Age, site, and
scanner-adjusted progression rates for men and women in
each racial ethnic group are provided in Table 3.
Statin use at exam 1 was associated with increased CAC.
Time-varying statin use was less strongly associated with
increased CAC. To fully explore the relationship between CAC
progression and statin use, we also evaluated statin use
categorically (described in “Methods”). CAC progression
among participants who were prescribed statins over the
course of follow-up was 5.2 Agatston units/year faster than
among participants who never took statins (95% CI 3.3 to
7.1). Among those who were taking statins at exam 1, CAC
progression was even higher.
Both smoking status and pack-years of smoking were
associated with increased CAC progression (Table 2). Over-
all, 401 participants reported never smoking at exam 1 but
later reported being former smokers. Using the MESA Lung
smoking status classification, 14 of these participants and
70 additional participants were assumed to be current
smokers. The remaining 387 participants were considered to
be former smokers. This strengthened the association
between smoking status and CAC progression for former
smokers compared with never smokers (5.3 Agatston units/
year [95% CI 2.5 to 8.1]) and had a minimal impact for
current smokers compared with never smokers (7.4 Agat-
ston units/year [95% CI 3.5 to 11.3]). Second-hand smoke
exposure was not associated with CAC progression (data not
shown).
As shown in Table 2, we observed associations between
CAC progression and many other CVD risk factors and
participant characteristics. These included family history of
premature CVD, BMI, diabetes, hypertension, blood pressure,
triglycerides, and HDL-C. Total cholesterol and LDL-C were
not associated with differences in CAC progression. None of
the markers of socioeconomic status—income, education, or
neighborhood socioeconomic status index—were associated
with CAC progression. Elevated C-reactive protein and
fibrinogen were associated with increased CAC progression,
but creatinine was not.
Results from the fully adjusted model are also presented in
Table 2. Associations between CAC progression and age at
exam 1, sex, BMI, hypertension, statin use, diabetes, and
family history of premature CVD were still strong but slightly
attenuated. The association between smoking status and CAC
progression was similar to the minimally adjusted result.
Associations for black race and Hispanic ethnicity were
greatly strengthened.
We performed a large number of sensitivity analyses, which
are shown in Tables 4 and 5. Our results were robust for
changes such as participant exclusions and variations in the
set of adjustment variables. We controlled for clinical center
in all primary analyses because the study design stratified
participant recruitment by race/ethnicity and study site;
however, site adjustment might not be necessary if the
differences were captured by control for other risk factors. We
found that site adjustment was not influential for most risk
factors but affected associations between race/ethnicity and
CAC progression (Table 4). Our results were not significantly
affected by control for scanner type.
Other sensitivity analyses excluded participants with
greater CAC progression to better understand their influence
on the results. Their exclusion generally reduced magnitudes
of association but also reduced standard errors. Conse-
quently, most relationships observed in the full data set
persisted, but estimates were reduced by 25% among
participants with CAC progression <250 Agatston units/year
(Table 5) or by about 40% among participants with CAC
progression <150 Agatston units/year. Excluding participants
with CAC below the scanner’s threshold (0 Agatston units) at
baseline, estimates were generally 20% to 50% more extreme.
Different relationships among the racial/ethnic groups were
observed in this subset than in the cohort overall, and that
may be related to a preferential exclusion of nonwhite
participants. Specifically, CAC progression was not signifi-
cantly different by race among participants with measureable
CAC at baseline.
Results from the analysis of annual change between exams
1 and 5 are presented in Table 6. These results are highly
consistent with results obtained from a mixed-effects model
analysis of the same subset of participants that attended
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Table 1. Selected Participant Characteristics at Exam 1
All Participants Participants With Any Follow-up Last Follow-up in Exam 5
N 6810 6066 3305
Follow-up time, y 5.8 (3.9) 6.5 (3.5) 9.6 (0.6)
Observations per Individual 2.5 (0.8) 2.7 (0.7) 3.2 (0.4)
Agatston Score at Exam 1 146 (417) 136 (383) 100 (295)
CAC progression, Agatston/year — 24 (57) 20 (39)
Age at exam 1, y 62 (10) 62 (10) 60 (9)
Male 3212 (47%) 2888 (48%) 1571 (48%)
Race/ethnicity
White 2621 (38%) 2401 (40%) 1303 (39%)
Chinese 804 (12%) 713 (12%) 385 (12%)
Black 1890 (28%) 1637 (27%) 883 (27%)
Hispanic 1495 (22%) 1315 (22%) 734 (22%)
Education
Less than high school 1247 (18%) 1031 (17%) 460 (14%)
High school 1234 (18%) 1093 (18%) 587 (18%)
Some college/technical 1937 (28%) 1731 (29%) 981 (30%)
College or graduate 2392 (35%) 2211 (36%) 1277 (39%)
Income, $10 000* 40 (21 to 69) 42 (23 to 51) 46 (26 to 75)
BMI, kg/m2 28.3 (5.5) 28.3 (5.4) 28.4 (5.3)
Systolic blood pressure, mm Hg 127 (21) 126 (21) 124 (20)
Diastolic blood pressure, mm Hg 72 (10) 72 (10) 72 (10)
Hypertension 3056 (45%) 2661 (44%) 1361 (41%)
Antihypertensive medication 2534 (37%) 2203 (36%) 1151 (35%)
LDL-C, mg/dL 117 (31) 117 (31) 118 (31)
HDL-C, mg/dL 51 (15) 51 (15) 51 (15)
Triglycerides, mg/dL 132 (89) 131 (86) 131 (82)
Statins 1009 (15%) 904 (15%) 486 (15%)
Smoking
Never 3234 (47%) 2879 (47%) 1590 (48%)
Former 2543 (37%) 2287 (38%) 1244 (38%)
Current 1011 (15%) 883 (15%) 466 (14%)
Second-hand smoke exposure 2255 (33%) 2060 (34%) 1213 (37%)
Pack-years of smoking 11 (21) 11 (21) 10 (20)
Diabetes
Not diabetic 4990 (73%) 4506 (74%) 2517 (76%)
Impaired fasting glucose 937 (14%) 828 (14%) 444 (13%)
Diabetes 859 (13%) 714 (12%) 335 (10%)
Family history of premature CVD† 1676 (27%) 1597 (27%) 897 (28%)
Fibrinogen, mg/dL 347 (74) 345 (73) 342 (71)
C-reactive protein, mg/dL 3.8 (5.9) 3.7 (5.6) 3.5 (5.2)
Continued
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exams 1 and 5, although many of the estimates are somewhat
lower than those in the analysis of the whole cohort.
Discussion
We found strong relationships between known risk factors for
CVD and progression of CAC over a 10-year period in a large
multiethnic population. We adopted an innovative approach to
statistical modeling to fully incorporate all data available from
>6000 subjects, regardless of their baseline CAC levels and
numbers of available scans. Our findings were robust for a
range of different data exclusions, refinements to the
outcome, and modeling details. These results do not inform
us about the prognoses for specific participants but rather
provide a framework that can be used to describe and
evaluate the importance of population-level characteristics,
interventions, and potential risk factors for atherosclerosis.
These advanced methods have expanded our understanding
of the progression of subclinical atherosclerosis, as measured
by coronary artery calcification.
The associations that we observed between CAC progres-
sion and risk factors were consistent with those of Kronmal
et al for BMI, family history of CVD, triglycerides, systolic blood
pressure, and pack-years of smoking.6 Also consistent with that
study was an observed lack of association between CAC
progression and LDL-C, education, or creatinine. That study
observed stronger associations between CAC progression and
race/ethnicity. Evidence from sensitivity analyses indicates
that this discrepancy is attributable primarily to adjustment for
site in our study. In both studies, race/ethnicity was more
strongly related to CAC progression in more fully adjusted
models, suggesting confounding between race/ethnicity and
risk factors such as smoking and BMI. This is further suggested
by the lack of robustness in the associations observed between
race/ethnicity and CAC progression in our sensitivity analyses
(Tables 4 and 5). The fact that race/ethnicity is more strongly
associated with CAC progression in some subsets of partici-
pants warrants further research.
We observed higher magnitudes of association in CAC
progression for age, sex, cigarette smoking status, HDL-C,
diabetes, antihypertensive medications, and statin use at
exam 1 compared with Kronmal et al.6 Because atheroscle-
rosis is a gradual process, a longer follow-up time presumably
enables more accurate estimation of the progression rate.
Other prior studies with shorter follow-up observed associa-
tions between CAC progression and white race,22 hyperten-
sion,22 diabetes,22 fibrinogen,23 HDL-C,24 and smoking.6,25 It
is difficult to make meaningful comparisons among these
studies due to differences in the study populations or
transformations of the outcome; however, we found that our
results were consistent with these studies in direction of
association.
Our findings regarding statin use in this cohort are mixed,
likely reflecting the current practice of prescribing statins for
those with multiple existing CVD risk factors and for those
with evidence of atherosclerosis. Additionally, statins likely
mitigate progression of atherosclerosis primarily in noncalci-
fied lesions. These features would have complex effects on
the speed of CAC progression. Others have also observed
uneven impact of lipid-lowering medications on CAC progres-
sion.3,24,26–30 Some prior studies have suggested that statin
use does not affect CAC progression,26,27,31,32 although these
studies were limited by relatively small sample sizes and/or
short follow-up times. In MESA, evidence from early exami-
nations indicated that participants on statins had increased
CAC progression compared with those not on statins,
presumably because they were already at higher risk.4,6 In
our study, statin use at exam 1 was strongly associated with
subsequent CAC progression, supporting the explanation that
the high-risk group was those who had already been
prescribed statins in the years 2000–2002. The association
with time-varying statin use over the subsequent 10 years,
when statin use became much more prevalent, was less
strong.
At least 1 study suggested that statin therapy could
increase the density of calcification by removing the lipids
from calcified plaques.33 This “defatting” process would
thereby increase pixel brightness and could inflate Agatston
CAC scores disproportionately relative to the amount of
plaque present. This implies that statins could prevent the
Table 1. Continued
All Participants Participants With Any Follow-up Last Follow-up in Exam 5
Creatinine, mg/dL
1.0 1210 (18%) 1110 (18%) 607 (18%)
≤0.9 3792 (56%) 3343 (55%) 1856 (56%)
≥1.1 1783 (26%) 1595 (26%) 833 (25%)
Data are shown mean (SD) or count (percentage). BMI indicates body mass index; CAC, coronary artery calcium; CVD, cardiovascular disease; HDL-C, high-density lipoprotein cholesterol;
LDL-C, low-density lipoprotein cholesterol.
*Median (interquartile range). Averaged across all exams.
†CVD in a male parent, child, or sibling before age 55 years or in a female relative before age 65 years. Reported during Exam 2.
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Table 2. Associations Between Risk Factors and CAC Progression (Agatston units/year)
Risk Factor
Minimally Adjusted Difference in Average
Annual Progression (95% CI)*
Fully Adjusted Difference in Average Annual
Progression (95% CI)†
Age at Exam 1, 10 years 14.2 (13.0 to 15.5) P<0.001 11.2 (9.8 to 12.5) P<0.001
Male sex 17.8 (15.3 to 20.3) P<0.001 16.4 (13.9 to 18.9) P<0.001
Race/ethnicity (ref: white) P=0.074 P<0.001
Chinese 4.3 (9.1 to 0.4) 3.0 (7.7 to 1.8)
Black 3.8 (7.1 to 0.6) 12.2 (15.5 to 8.9)
Hispanic 2.7 (6.6 to 1.1) 7.5 (11.2 to 3.7)
Education (ref: less than high school) P=0.46
High school 0.5 (4.8 to 3.9)
Some college/technical 0.9 (3.2 to 5.0)
College or graduate 1.7 (5.9 to 2.5)
Income, $10 000‡ 0.4 (0.8 to 0.0) P=0.066
Body mass index, 5 kg/m2 5.1 (3.9 to 6.3) P<0.001 2.6 (1.3 to 3.8) P<0.001
Systolic blood pressure, 10 mm Hg 1.9§k (1.3 to 2.6) P<0.001 0.9 (0.2 to 1.7) P=0.016
Diastolic blood pressure, 10 mm Hg 1.7§k (0.4 to 3.0) P=0.009
Hypertension 13.8 (11.2 to 16.5) P<0.001 7.5 (4.3 to 10.6) P<0.001
Antihypertensive medications 11.2k (7.5 to 14.8) P<0.001
LDL-C, 10 mg/dL 0.0¶ (0.4 to 0.4) P=0.99
HDL-C, 10 mg/dL 1.8¶ (2.7 to 0.9) P<0.001
Triglycerides, log mg/dL 6.0¶ (3.5 to 8.4) P<0.001
Total cholesterol, 10 mg/dL 0.1¶ (0.2 to 0.5) P=0.45
Statin use at exam 1 12.8 (9.3 to 16.4) P<0.001 6.4 (3.0 to 9.9) P<0.001
Statin use, time varying# 3.9 (2.2 to 5.5) P<0.001
Smoking (ref: never) P<0.001 P<0.001
Former 4.1 (1.3 to 6.9) 4.2 (1.5 to 6.9)
Current 7.1 (3.1 to 11.1) 7.8 (3.9 to 11.7)
10 pack-years of smoking 1.2** (0.5 to 2.0) P<0.001
Diabetes (ref: not diabetic) P<0.001 P<0.001
Impaired fasting glucose 5.9 (2.2 to 9.5) 3.4 (0.2 to 7.1)
Diabetes 31.3 (27.4 to 35.3) 26.5 (22.5 to 30.5)
Family history of premature CVD†† 8.0 (5.2 to 10.9) P<0.001 5.5 (2.7 to 8.2) P<0.001
Neighborhood SES index, IQR 0.0 (1.7 to 1.7) P=0.99
Fibrinogen, 100 mg/dL 5.6 (3.8 to 7.4) P<0.001
C-reactive protein, log mg/dL 2.1 (0.9 to 3.2) P<0.001
Creatinine (Ref: 1.0 mg/dL) P=0.82
≤0.9 mg/L 0.5 (4.1 to 3.1)
≥1.1 mg/dL 1.2 (5.1 to 2.6)
All risk factors were measured at exam 1 except as indicated. Mean CAC progression was 23.9 Agatston units/year among all participants. CAC indicates coronary artery calcium; CVD,
cardiovascular disease; CT, computed tomography; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SES, socioeconomic status.
*Minimally adjusted models include age, sex, race/ethnicity, site, and CT scanner type along with the reported term.
†Adjustment model determined by backward selection on participants’ slopes as outcome; all terms reported in the table, plus site and CT scanner type were in the model.
‡Averaged across all exams.
§Additionally adjusted for antihypertensive medication use at exam 1.
kAdditionally adjusted for hypertension status.
¶Additionally adjusted for statin use.
#As reported at each exam.
**Additionally adjusted for smoking status.
††
CVD in a male parent, child, or sibling before age 55 years or in a female relative before age 65 years. Reported during exam 2.
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deposition of new CAC while still increasing the Agatston
score. If this were true, we might expect to observe that those
prescribed statins during the course of follow-up would have
the highest CAC progression because, presumably, much of
this change in plaque architecture would have occurred prior
to scanning among the participants that were already on
statins at exam 1. Instead, we observed that CAC progression
was fastest among participants using statins at exam 1. This
would suggest that statins promote coronary atheroma
calcification, even though they are known to regress plaque
extent; statins might help stabilize plaques by increasing the
density of calcium. A recent evaluation of 3495 participants
imaged with intravascular ultrasound in clinical trials indicated
that high-intensity statin therapy was associated with
increases in coronary atheroma calcification independent of
the plaque-regressive effects.34 The attenuation of the
association between statin use and CAC progression in the
fully adjusted model suggests some residual confounding.
Whatever mechanism is responsible for the observed asso-
ciation between CAC progression and statin use would also
induce a lack of association with LDL-C.
Because participants were advised of their CAC scores, it
raises the prospect that this information led to changes in risk
factors and treatments, which in turn affects subsequent
progression rates. In fact, prior investigators9 found that
higher CAC scores at baseline in MESA were associated with
increased initiation of lipid-lowering agents. The use of these
agents and other preventive therapies during the period of
follow-up (as at baseline) is subject to “confounding by
indication”35 because CAC at baseline is associated with
subsequent progression. This may make it difficult to interpret
the use of these agents in the progression model and to
interpret the measures that are strongly affected by these
treatments such as total cholesterol and LDL-C. Because our
model adjusts fully, in a time-varying manner, for the use of
lipid-lowering agents, the interpretation of factors not directly
related to these therapies—which are the focus of this paper
—should not be confounded.
A limitation of this study is the potential for selection bias.
Although participants with no follow-up contribute to our
analysis in the cross-sectional exam 1 characterization, they
do not directly contribute to the estimation of the progression
rate. Participants who had no follow-up, particularly those who
died or became too sick to continue the study between exams
1 and 2, may differ from those with follow-up measurements;
however, the overall retention rate was high, and the mixed-
effects model approach allows the analysis to be adjusted for
variables related to health status. Consequently, we expected
the impact of selection bias on these results to be minimal.
CAC data are well known to be highly skewed, which
makes individual-level modeling difficult. The parameter that
we investigated in this study, a mean summarizing a skewed
distribution of progression, describes population-level
atherosclerotic burden. It is necessarily true that the estimate
of the coefficient relevant to this parameter is highly
influenced by the relative number of participants with high
progression rates and by the magnitude of those rates.
Studies that use this method of assessing subclinical
atherosclerotic progression will need to examine the relative
magnitudes of progression of traditional risk factors to create
the appropriate context for results for novel risk factors.
The fact that these results are consistent with those of
Kronmal et al despite the inclusion of a large number of
participants with no CAC at baseline lends credence to the
idea that CAC progression modeled as a single process is
informative. This result is important because no concise
summary could be generated from separately modeled time to
Table 3. Annual Progression Rates (Agatston units/year) for
Men and Women in Each Racial/Ethnic Group
Female Male
White 16.9 41.2
Chinese 17.7 31.2
Black 19.5 29.9
Hispanic 17.3 35.0
Rates are based on a mixed-effects model including interactions between race/ethnicity
and sex and are adjusted for age, site, and scanner.
Table 4. Associations Between Race/Ethnicity and CAC Progression: Sensitivity to Adjustment Model
Risk Factor Not Adjusted for Site, Adjusted for Scanner Adjusted for Site, Not Adjusted for Scanner Not Adjusted for Site, Not Adjusted for Scanner
Race/ethnicity (ref: white) P=0.003 P=0.13 P=0.010
Chinese 6.2 (10.4 to 2.0) 4.1 (8.9 to 0.7) 6.1 (10.3 to 2.0)
Black 5.1 (8.2 to 1.9) 3.3 (6.6 to 0.1) 4.0 (7.1 to 0.9)
Hispanic 2.3 (5.6 to 1.1) 2.6 (6.4 to 1.2) 2.5 (5.8 to 0.8)
Values are differences in annual CAC progression in Agatston units/year. Models included age and sex. Mean CAC progression was 23.9 Agatston units/year among all participants. Other
risk factors investigated were not substantially (<20% change) affected by the adjustment models specified. CAC indicates coronary artery calcium.
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Table 5. Associations Between Risk Factors and CAC Progression: Sensitivity to Participant Exclusions
Risk Factor
Progression >250 Units/Year
Excluded (n=6664)
Progression >150 Units/Year
Excluded (n=6539) Complete Covariates (n=5958) CAC >0 at Exam 1 (n=3395)
Age at exam 1,
10 years
11.1 (10.1 to 12.1) P<0.001 8.9 (8.1 to 9.7) P<0.001 13.8 (12.6 to 15.1) P<0.001 12.8 (10.2 to 15.4) P<0.001
Male sex 14.1 (12.2 to 16.0) P<0.001 11.0 (9.5 to 12.6) P<0.001 17.0 (14.5 to 19.5) P<0.001 19.5 (14.6 to 24.4) P<0.001
Race/ethnicity
(ref: white)
P=0.003 P<0.001 P=0.29 P=0.70
Chinese 3.2 (6.9 to 0.4) 3.1 (6.1 to 0.1) 4.0 (8.8 to 0.8) 0.5 (9.7 to 8.7)
Black 4.6 (7.1 to 2.1) 4.4 (6.5 to 2.4) 4.7 (8.0 to 1.4) 2.9 (3.5 to 9.4)
Hispanic 2.2 (5.1 to 0.7) 1.4 (3.8 to 1.0) 2.7 (6.6 to 1.2) 3.1 (4.4 to 10.6)
Education
(ref: less than
high school)
P=0.15 P=0.15 P=0.33 P=0.26
High school 1.8 (1.5 to 5.1) 1.9 (0.9 to 4.6) 0.1 (4.6 to 4.4) 6.1 (14.4 to 2.2)
Some
college/
technical
2.2 (0.9 to 5.3) 2.5 (0.0 to 5.1) 1.8 (2.4 to 6.0) 2.1 (10.0 to 5.9)
College or
graduate
0.3 (3.5 to 2.9) 0.8 (1.9 to 3.4) 1.3 (5.6 to 3.1) 6.5 (14.6 to 1.5)
Income, $10 000* 0.3 (0.6 to 0.1) P=0.12 0.2 (0.5 to 0.0) P=0.11 0.4 (0.8 to 0.1) P=0.10 0.8 (1.6 to 0.0) P=0.051
Body mass
index, 5 kg/m2
3.8 (2.8 to 4.7) P<0.001 3.3 (2.5 to 4.1) P<0.001 5.2 (4.0 to 6.5) P<0.001 8.0 (5.5 to 10.5) P<0.001
Systolic blood
pressure,
10 mm Hg†
1.6 (1.1 to 2.1) P<0.001 1.2 (0.8 to 1.7) P<0.001 1.9 (1.3 to 2.6) P<0.001 3.1 (1.9 to 4.3) P<0.001
Diastolic
blood pressure,
10 mm Hg†
2.2 (1.2 to 3.2) P<0.001 1.5 (0.6 to 2.3) P<0.001 1.7 (0.4 to 3.0) P=0.013 3.5 (1.0 to 6.0) P=0.007
Hypertension 10.4 (8.4 to 12.5) P<0.001 8.1 (6.4 to 9.8) P<0.001 14.5 (11.8 to 17.2) P<0.001 19.2 (14.2 to 24.2) P<0.001
Antihypertensive
medications‡
7.5 (4.8 to 10.3) P<0.001 5.7 (3.4 to 8.0) P<0.001 10.3 (6.7 to 14.0) P<0.001 15.0 (8.5 to 21.4) P<0.001
LDL-C, 10 mg/dL§ 0.3 (0.0 to 0.6) P=0.08 0.4 (0.1 to 0.6) P=0.003 0.0 (0.4 to 0.4) P=0.92 0.7 (1.5 to 0.1) P=0.08
HDL-C, 10 mg/dL§ 1.3 (2.0 to 0.6) P<0.001 1.3 (1.9 to 0.7) P<0.001 2.1 (3.1 to 1.2) P<0.001 2.3 (4.2 to 0.5) P=0.01
Triglycerides,
log mg/dL§
6.2 (4.4 to 8.1) P<0.001 4.9 (3.4 to 6.4) P<0.001 7.1 (4.5 to 9.7) P<0.001 10.4 (5.6 to 15.2) P<0.001
Total cholesterol,
10 mg/dL§
0.4 (0.2 to 0.7) P=0.002 0.4 (0.2 to 0.6) P<0.001 0.0 (0.3 to 0.4) P=0.82 0.2 (0.9 to 0.6) P=0.67
Statin use at exam 1 9.0 (6.3 to 11.8) P<0.001 7.3 (5.0 to 9.5) P<0.001 11.1 (7.6 to 14.7) P<0.001 13.2 (7.1 to 19.2) P<0.001
Statin use,
time varyingk
4.9 (3.6 to 6.3) P<0.001 4.3 (3.2 to 5.5) P<0.001 3.5 (1.8 to 5.2) P<0.001 4.0 (0.7 to 7.3) P=0.017
Smoking (ref: never) P<0.001 P<0.001 P<0.001 P=0.20
Former 4.2 (2.1 to 6.3) 4.1 (2.3 to 5.8) 4.9 (2.0 to 7.7) 3.4 (2.0 to 8.7)
Current 6.4 (3.3 to 9.4) 5.6 (3.2 to 8.1) 7.0 (2.8 to 11.1) 6.8 (1.3 to 14.8)
10 pack-years
of smoking¶
1.3 (0.7 to 1.9) P<0.001 1.8 (1.3 to 2.4) P<0.001 1.3 (0.6 to 2.1) P<0.001 0.5 (0.7 to 1.8) P=0.39
Diabetes
(ref: not diabetic)
P<0.001 P<0.001 P<0.001 P<0.001
Impaired
fasting glucose
4.3 (1.5 to 7.1) 3.8 (1.5 to 6.1) 6.3 (2.6 to 10.0) 9.8 (3.2 to 16.4)
ContinuedContinued
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progression and progression rate, as would be necessary for
data that are unbalanced in time.
We noted that results from the mixed-effects model were
also consistent with the results obtained from a simple
change analysis. Because both methods should lead to valid
conclusions, we would expect these results to be similar.
There are 2 main drawbacks to the change analysis: (1) No
time-varying information can be included, and (2) the analysis
must be restricted to a more selected subset of participants
than the mixed-effects model analysis. These 2 facts mean
that simple adjustment is less accurate (due to less control of
scanner and other time-varying effects), and the results are
less generalizable than those derived from the full mixed-
effects model analysis.
The major strengths of this analysis include the substantial
follow-up time, the well-characterized prospective cohort, and
our application of mixed-effects models to this question.
Baseline CAC and CAC progression rate are associated, but
control for measured baseline can lead to bias.19,20 The linear
mixed-effects model effectively controls for the baseline CAC
and permits an unbiased understanding of both cross-
sectional and longitudinal relationships between risk factors
and CAC. It also allows us to appropriately account for
repeated measures and variable follow-up times. Including 3
or 4 measurements for more than half the cohort permits
more accurate estimation of uncertainty compared with study
designs that include only 2 measurements per participant.
Finally, by not using a logarithmically transformed CAC score
in our analysis, as others have used,28,30 we did not give extra
weight to the lower CAC scores, which convey less informa-
tion about the quantity of interest and may be subject to more
impact of transitions in scanner technology. We examined the
associations among the lower calcium scores in a sensitivity
analysis by calculating spatially weighted calcium scores36 for
participants with an Agatston score of 0, but the results were
essentially identical to those obtained using the Agatston
score alone.
Conclusions
Coronary artery calcification by CT scan is a useful and
noninvasive measure of the extent of atherosclerosis. This
study examined a comprehensive set of risk factors for CAC
progression over a long period of follow-up in a well-studied
population that was selected to be free of clinical CVD at
baseline. Our analysis used an innovative application to the
study of CVD epidemiology. It relied on a statistical approach
for progression analysis that is both less prone to bias and
more flexible than other methods used previously to study
atherosclerosis progression. The mixed-effects model method
can also be applied to evaluating novel risk factors. We found
that CAC progression over 10 years was strongly associated
Table 5. Continued
Risk Factor
Progression >250 Units/Year
Excluded (n=6664)
Progression >150 Units/Year
Excluded (n=6539) Complete Covariates (n=5958) CAC >0 at Exam 1 (n=3395)
Diabetes 22.7 (19.6 to 25.7) 17.9 (15.4 to 20.5) 31.8 (27.7 to 35.9) 45.5 (38.7 to 52.4)
Family history
of CVD#
7.9 (5.7 to 10.0) P<0.001 6.0 (4.3 to 7.8) P<0.001 7.8 (4.9 to 10.6) P<0.001 10.6 (5.2 to 16.0) P<0.001
Neighborhood
SES index, IQR
0.0 (1.3 to 1.2) P=0.98 0.1 (1.0 to 1.1) P=0.88 0.6 (1.1 to 2.2) P=0.50 0.1 (3.3 to 3.1) P=0.93
Fibrinogen,
100 mg/dL
4.5 (3.1 to 5.9) P<0.001 3.9 (2.8 to 5.0) P<0.001 5.0 (3.1 to 6.8) P<0.001 6.0 (2.6 to 9.5) P<0.001
C-reactive
protein, log mg/dL
1.5 (0.7 to 2.4) P<0.001 1.4 (0.7 to 2.1) P<0.001 2.1 (1.0 to 3.3) P<0.001 3.0 (0.8 to 5.3) P=0.008
Creatinine
(ref: 1 mg/dL)
P=0.61 P=0.84 P=0.91 P=0.94
≤0.9 1.2 (3.9 to 1.5) 0.6 (2.8 to 1.7) 0.3 (3.4 to 3.9) 0.6 (7.3 to 6.1)
≥1.1 1.3 (4.3 to 1.6) 0.7 (3.1 to 1.8) 0.5 (4.4 to 3.4) 1.2 (8.1 to 5.7)
Values are differences in annual CAC progression in Agatston units/year. Models included age, sex, race/ethnicity, site, and scanner type. All risk factors were measured at exam 1 except
as indicated. Mean CAC progression was 23.9 Agatston units/year among all participants. CAC indicates coronary artery calcium; CVD, cardiovascular disease; HDL-C, high-density
lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SES, socioeconomic status.
*Averaged across all exams.
†Additionally adjusted for antihypertensive medication use at baseline.
‡Additionally adjusted for hypertension status.
§Additionally adjusted for statin use.
kAs reported at each exam.
¶Additionally adjusted for smoking status.
#CVD in a male parent, child, or sibling before age 55 years or in a female relative before age 65 years. Reported during exam 2.
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Table 6. Comparison to Analysis Change Between Exams 1 and 5
Annual Change, Exam 1 to 5* Mixed-effects Model, Participants Attending Exam 5†
Age at Exam 1, 10 years 9.8 (8.5 to 11.1) P<0.001 10.4 (9.1 to 11.7) P<0.001
Male sex 12.4 (10.0 to 14.8) P<0.001 13.6 (11.2 to 16.1) P<0.001
Race/ethnicity (ref: white) P=0.26 P=0.13
Chinese 0.3 (4.9 to 4.3) 0.9 (5.5 to 3.8)
Black 2.3 (5.6 to 1.0) 3.0 (6.2 to 0.2)
Hispanic 1.2 (4.9 to 2.4) 1.5 (5.2 to 2.3)
Education (ref: less than high school) P=0.26 P=0.12
High school 3.1 (1.4 to 7.6) 3.8 (0.7 to 8.3)
Some college/technical 3.3 (0.9 to 7.5) 2.9 (1.4 to 7.1)
College or graduate 0.0 (4.3 to 4.3) 0.3 (4.0 to 4.6)
Income, $10 000‡ 0.2 (0.7 to 0.2) P=0.24 0.3 (0.7 to 0.1) P=0.13
Body mass index, 5 kg/m2 3.8 (2.5 to 5.0) P<0.001 4.3 (3.1 to 5.5) P<0.001
Systolic blood pressure, 10 mm Hg§ 1.9 (1.2 to 2.5) P<0.001 1.9 (1.3 to 2.6) P<0.001
Diastolic blood pressure, 10 mm Hg§ 2.1 (0.8 to 3.4) P<0.001 2.1 (0.8 to 3.4) P=0.002
Hypertension 10.5 (7.9 to 13.1) P<0.001 11.5 (8.9 to 14.1) P<0.001
Antihypertensive medicationsk 9.5 (5.9 to 13.2) P<0.001 9.8 (6.2 to 13.5) P<0.001
LDL-C, 10 mg/dL¶ 0.0 (0.4 to 0.4) P=0.92 0.1 (0.3 to 0.5) P=0.50
HDL-C, 10 mg/dL¶ 1.4 (2.3 to 0.5) P<0.001 1.7 (2.7 to 0.8) P<0.001
Triglycerides, log mg/dL¶ 5.4 (3.0 to 7.8) P<0.001 6.5 (4.0 to 8.9) P<0.001
Total cholesterol, 10 mg/dL¶ 0.1 (0.2 to 0.5) P=0.06 0.2 (0.1 to 0.6) P=0.18
Statin use at exam 1 8.7 (5.2 to 12.2) P<0.001 8.6 (5.1 to 12.1) P<0.001
Statin use, time varying# — — 4.5 (2.8 to 6.3) P<0.001
Smoking (ref: never) P<0.001 P=0.007
Former 3.5 (0.8 to 6.2) 3.6 (0.8 to 6.3)
Current 4.4 (0.5 to 8.4) 4.8 (0.8 to 8.8)
10 pack-years of smoking** 1.5 (0.7 to 2.2) P<0.001 1.3 (0.6 to 2.1) P<0.001
Diabetes (ref: not diabetic) P<0.001 P<0.001
Impaired fasting glucose 3.3 (0.2 to 6.8) 3.7 (0.1 to 7.2)
Diabetes 26.0 (21.9 to 30.1) 27.6 (23.5 to 31.6)
Family history of CVD†† 4.8 (2.1 to 7.5) P=0.007 4.9 (2.2 to 7.6) P<0.001
Neighborhood SES index, IQR 0.1 (1.7 to 1.5) P=0.27 0.1 (1.5 to 1.7) P=0.87
Fibrinogen, 100 mg/dL 3.8 (2.0 to 5.6) P<0.001 4.7 (2.9 to 6.5) P<0.001
C-reactive protein, log mg/dL 0.3 (0.1 to 0.6) P=0.003 0.4 (0.2 to 0.6) P<0.001
Creatinine (ref: 1 mg/dL) P=0.82 P=0.48
≤0.9 0.8 (4.3 to 2.7) 1.5 (5.0 to 2.0)
≥1.1 1.2 (4.9 to 2.6) 0.8 (4.6 to 3.0)
Results from the primary analysis are repeated in this table for easy comparison (left) alongside the results from multiple linear regression of risk factors on the annual change between
exams 1 and 5 (center). Results from mixed-effects models restricted to the subset of participants with measurements at both exams 1 and 5 are also presented (right). CVD indicates
cardiovascular disease; CT, computed tomography; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SES, socioeconomic status.
*Annual change=(exam 5exam 1)/(time in years). Results are adjusted for the CT scanner model used at exams 1 and 5 and for the interaction between the 2 scanner types.
†Includes observations intermediate between exam 1 and exam 5.
‡Averaged across all exams.
§Additionally adjusted for antihypertensive medication use at baseline.
kAdditionally adjusted for hypertension status.
¶Additionally adjusted for statin use.
#As reported at each exam.
**Additionally adjusted for smoking status.
††CVD in a male parent, child, or sibling before age 55 years or in a female relative before age 65 years. Reported during exam 2.
DOI: 10.1161/JAHA.114.001726 Journal of the American Heart Association 12
Predictors of Long-Term CAC Progression in MESA Gassett et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
with most CVD risk factors, confirming that risk factors for
clinical coronary disease and the progression of CAC are
overlapping.
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